TY - JOUR
T1 - Oral contraceptives and the risk of focal nodular hyperplasia of the liver
T2 - A case-control study
AU - Scalori, Astrid
AU - Tavani, Alessandra
AU - Gallus, Silvano
AU - La Vecchia, Carlo
AU - Colombo, Massimo
PY - 2002
Y1 - 2002
N2 - OBJECTIVE: A role of female hormones, including oral contraceptives, has been suggested in the etiology of focal nodular hyperplasia of the liver. There is, however, no epidemiologic quantification of this relationship. STUDY DESIGN: A hospital-based case-control study was conducted in Italy of 23 women with histologically confirmed focal nodular hyperplasia of the liver and 94 controls in the hospital for acute diseases. Odds ratios (ORs) were computed by use of multiple logistic regression models. RESULTS: Focal nodular hyperplasia was not associated with menstrual and reproductive factors. Ever oral contraceptive use was reported by 83% of cases and 59% of controls. The multivariate OR was 2.8 (95% confidence interval [CI], 0.8-9.4) for ever use, and 4.5 (95% CI, 1.2-16.9) for use ≥3 years. The trend in risk with duration was statistically significant. CONCLUSIONS: This study confirms previous clinical observations, and provides a quantitative estimate of the association between use of oral contraceptives and focal nodular hyperplasia of the liver.
AB - OBJECTIVE: A role of female hormones, including oral contraceptives, has been suggested in the etiology of focal nodular hyperplasia of the liver. There is, however, no epidemiologic quantification of this relationship. STUDY DESIGN: A hospital-based case-control study was conducted in Italy of 23 women with histologically confirmed focal nodular hyperplasia of the liver and 94 controls in the hospital for acute diseases. Odds ratios (ORs) were computed by use of multiple logistic regression models. RESULTS: Focal nodular hyperplasia was not associated with menstrual and reproductive factors. Ever oral contraceptive use was reported by 83% of cases and 59% of controls. The multivariate OR was 2.8 (95% confidence interval [CI], 0.8-9.4) for ever use, and 4.5 (95% CI, 1.2-16.9) for use ≥3 years. The trend in risk with duration was statistically significant. CONCLUSIONS: This study confirms previous clinical observations, and provides a quantitative estimate of the association between use of oral contraceptives and focal nodular hyperplasia of the liver.
KW - Case-control studies
KW - Hormones
KW - Liver focal nodular hyperplasia
KW - Oral contraceptives
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=0036175707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036175707&partnerID=8YFLogxK
U2 - 10.1067/mob.2002.120277
DO - 10.1067/mob.2002.120277
M3 - Article
C2 - 11854634
AN - SCOPUS:0036175707
SN - 0002-9378
VL - 186
SP - 195
EP - 197
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 2
ER -